BusinessCellular Biomedicine Group (CBMG) Announces Publication Titled “Target cell killing effects of CD20 targeting chimeric antigen receptor T cells derived from the type II anti-CD20 antibody” in Conjunction with 2017 ASCO Annual MeetingBy Nasdaq OMXMay 19, 2017, 12:29 PM UTC
BusinessCellular Biomedicine Group (CBMG) Announces Publication Titled “Target cell killing effects of CD20 targeting chimeric antigen receptor T cells derived from the type II anti-CD20 antibody” in Conjunction with 2017 ASCO Annual MeetingBy Nasdaq OMXMay 19, 2017, 12:29 PM UTC
BusinessCellular Biomedicine Group (CBMG) Announces the Addition of a Second Clinical Site in the Expansion of its Chimeric Antigen Receptor T-cell (CAR-T) Phase I Clinical Trial for Its CARD-1 Trial in Patients with Non-Hodgkin Lymphoma (NHL)By Nasdaq OMXMay 15, 2017, 10:22 AM UTC
BusinessCellular Biomedicine Group Reports First Quarter 2017 Financial Results and Provides Business HighlightsBy Nasdaq OMXMay 8, 2017, 8:03 PM UTC
BusinessCellular Biomedicine Group Reports First Quarter 2017 Financial Results and Provides Business HighlightsBy Nasdaq OMXMay 8, 2017, 8:03 PM UTC
BusinessCellular Biomedicine Group Reports First Quarter 2017 Financial Results and Provides Business HighlightsBy Nasdaq OMXMay 8, 2017, 8:03 PM UTC
BusinessCellular Biomedicine Group (CBMG) and GE Healthcare Life Sciences China Announce Strategic Partnership to Establish Joint Technology Laboratory to Develop Control Processes for the Manufacture of CAR-T and Stem Cell TherapiesBy Nasdaq OMXApr 10, 2017, 12:08 PM UTC
BusinessCellular Biomedicine Group (CBMG) and GE Healthcare Life Sciences China Announce Strategic Partnership to Establish Joint Technology Laboratory to Develop Control Processes for the Manufacture of CAR-T and Stem Cell TherapiesBy Nasdaq OMXApr 10, 2017, 12:08 PM UTC
